Structural basis for inhibition of SpyCas9 by the anti-CRISPR protein AcrIIA26
Biochemical Journal · 2026
DOI: 10.1042/bcj20250364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2026. Verfasst von Iris Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, U.S.A. Hauptthemen laut MEDLINE: Streptococcus pyogenes, CRISPR-Associated Protein 9, CRISPR-Cas Systems, Viral Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
CRISPR–Cas9 systems provide adaptive immunity in prokaryotes by targeting and cleaving invading phage DNA. In response, phages have evolved anti-CRISPR (Acr) proteins to inhibit Cas9 and evade this immune response. AcrIIA26 is a type II-A anti-CRISPR protein that inhibits Streptococcus pyogenes Cas9 (SpyCas9) DNA binding, but its molecular mechanism remains unclear. Here, we determined the 3.0 Å resolution cryo-EM structure of AcrIIA26 in complex with SpyCas9–single-guide RNA, revealing a dual inhibition mechanism. AcrIIA26 adopts a novel fold comprising a central β-sheet flanked by two α-helical bundles. The 5-helix bundle, which features a negatively charged surface whose shape mimics duplex DNA, occupies the same position as the protospacer adjacent motif (PAM) duplex in target-bound Cas9. This directly blocks PAM recognition by burying critical residues R1333 and R1335 in the PAM-interacting domain. Mutagenesis confirmed that residues E49 and D50 in AcrIIA26 are essential for this interaction. Simultaneously, the 4-helix bundle binds the Cas9 REC lobe and sterically prevents the conformational changes required for Cas9 activation, with mutation of AcrIIA26 F121 completely eliminating inhibitory activity. Structural comparisons reveal that despite diverse folds, multiple anti-CRISPRs convergently evolved to block PAM recognition, highlighting this as a critical vulnerability in Cas9 function. Our findings provide mechanistic insights into AcrIIA26 inhibition and offer a foundation for engineering improved Cas9 off-switches for genome editing applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, U.S.A.
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, U.S.A.
ORCID-Profile: Scott Bailey
Förderung
- NIGMS NIH HHS
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Zheng, I., Learn, B., & Bailey, S. (2026). Structural basis for inhibition of SpyCas9 by the anti-CRISPR protein AcrIIA26. Biochemical Journal. https://doi.org/10.1042/bcj20250364
Vancouver
Zheng I, Learn B, Bailey S. Structural basis for inhibition of SpyCas9 by the anti-CRISPR protein AcrIIA26. Biochemical Journal. 2026. doi:10.1042/bcj20250364
BibTeX
@article{Zheng2026,
author = {Zheng, Iris and Learn, Brian and Bailey, Scott},
title = {Structural basis for inhibition of SpyCas9 by the anti-CRISPR protein AcrIIA26},
journal = {Biochemical Journal},
year = {2026},
doi = {10.1042/bcj20250364}
}
EUVIMED